Life sciences venture investing has a longer timeline compared to tech investments, with developments taking a decade to gain approval for testing.
Advances in labware and AI have accelerated development timelines in life sciences, allowing assets to show promise and scalability within a decade.
The life of a life sci VC involves meeting innovative founders and witnessing breakthrough solutions to challenges, making it a fascinating experience.
The author decides to simulate the VC experience to test hypotheses and explore the world of venture investing in life sciences.
The simulated 'VC fund' will track investment decisions over a 3-year period to evaluate success at both individual and fund levels.
The author will base due diligence on publicly available information, refraining from specific company endorsements or considerations of fundraising activities.
Financials will be approximated, with adjustments made for real-life financial events occurring within 3 months of a decision.
Investment documents will be password protected with an 8-month delay to prevent misuse and will be publicly available for download.
Follow-on documents will be generated as events unfold around each investment, providing market analysis, portfolio management, and corrections.
The author will share due diligence posts on topics like cell therapy, genetic engineering, and vaccines, aiming to build a decision-making framework in biotech and healthcare.